Core Insights - LENZ Therapeutics has launched a consumer campaign called "Make it VIZZable" featuring Sarah Jessica Parker as the brand ambassador for VIZZ, an eye drop solution aimed at treating age-related blurry near vision [3][6] - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is available by prescription [11][12] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, impacting approximately 1.8 billion people globally and 128 million in the U.S. [15] - The company is headquartered in San Diego, California, and is establishing international licensing partnerships to expand access to VIZZ [15] Product Details - VIZZ is a once-daily eye drop that improves near vision by creating a pinhole effect through the contraction of the iris sphincter muscle, allowing for better depth of focus without causing a myopic shift [8][11] - In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes, lasting up to 10 hours [8] Market Context - Age-related blurry near vision, or presbyopia, affects nearly all individuals over the age of 45, with symptoms becoming pronounced in their mid-40s [10] - The gradual progression of presbyopia often leads to an abrupt need for corrective aids, such as reading glasses, impacting daily life significantly [7][10]

Core Insights - LENZ Therapeutics launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025, marking it as the first and only aceclidine-based eye drop for presbyopia treatment, with broad availability by mid-November 2025 [1][5] - The company reported approximately $1.6 million in net product revenue and over 20,000 prescriptions filled in Q4 2025, indicating strong initial market acceptance [1][7] - More than 6,500 unique eye care professionals (ECPs) prescribed VIZZ, with over 55% prescribing it multiple times, reflecting early confidence in the product [2][7] Commercial Highlights - The first commercial sale of VIZZ occurred in October 2025, with full multi-channel access established through e-pharmacy and nearly all retail pharmacies by mid-November 2025 [7] - The rapid uptake by prescribing ECPs is notable, with over 6,500 unique ECPs participating in the prescription process [7] Corporate Updates - In January 2026, LENZ announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East, which includes upfront, regulatory, and commercial milestone payments, along with a significant revenue share [4] - This partnership represents the fourth commercialization agreement for VIZZ outside the United States, indicating the company's strategy to expand its international presence [4] Product Information - VIZZ is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [9] - The product is indicated for age-related blurry near vision (presbyopia) in adults, a condition affecting approximately 1.8 billion people globally [5][10]

Core Insights - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting for the commercialization of VIZZ in the Middle East, which includes revenue sharing and milestone payments [1][2][3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved eye drop for presbyopia, impacting approximately 1.8 billion people globally and 128 million in the U.S. [9] - Lunatus is a Dubai-based pharmaceutical company specializing in the commercialization of healthcare products in the Middle East, established in 2003 [10] Product Information - VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing aceclidine as the active ingredient [5] - The product is preservative-free and provided in single-dose vials, offering a pupil-selective miotic effect to improve vision [5] Market Context - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, aimed at expanding access to presbyopia treatment in key strategic regions [3] - Presbyopia affects nearly all individuals over the age of 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [4]

Core Insights - Lotus Pharmaceutical has submitted a New Drug Application (NDA) for VIZZ in South Korea, marking the second regulatory submission for the drug outside the U.S. [1] - The NDA submission is backed by positive results from three Phase 3 studies in the U.S., demonstrating VIZZ's effectiveness in improving near vision [2] - Under the licensing agreement, LENZ Therapeutics stands to receive up to $125 million in milestone payments and royalties from future sales of VIZZ [3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, which affects approximately 1.8 billion people globally [10] - Lotus Pharmaceutical, founded in 1966, is an international pharmaceutical company with a strong R&D and manufacturing platform, certified by major regulatory authorities [11] Product Information - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free [6] - The drug is indicated for the treatment of age-related blurry near vision (presbyopia) in adults [7] Market Context - Presbyopia affects nearly all individuals over the age of 45, with significant implications for daily activities and quality of life [5] - The NDA submission in South Korea is part of a broader strategy to expand VIZZ's market presence in Southeast Asia, including countries like Thailand, Vietnam, and Malaysia [3]

Core Insights - LENZ Therapeutics, Inc. has received FDA approval for VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia, marking it as the first and only aceclidine-based eye drop approved for this condition [1][5][17] - The commercial launch of VIZZ began in October 2025, with broad availability expected by mid-Q4 2025 [1][5] - The company has partnered with Sarah Jessica Parker for a direct-to-consumer campaign, set to launch in Q1 2026 [1][2][5] Commercial Highlights - Over 2,500 Eye Care Professionals (ECPs) have prescribed VIZZ, with 40% of them prescribing multiple times, leading to over 5,000 prescriptions filled by October 2025 [1][2][5] - Awareness of VIZZ among ECPs reached 90% in October 2025, supported by extensive marketing efforts including 17,000 unique ECPs detailed and over 5 million digital campaign impressions [5] - The company has provided nearly 70,000 product samples to approximately 7,000 ECP offices, contributing to increased confidence in prescribing VIZZ [5] Financial Overview - As of September 30, 2025, the company reported pro forma cash, cash equivalents, and marketable securities of approximately $324.0 million, which is expected to support operations until post-launch positive cash flow [1][6] - Selling, General and Administrative (SG&A) expenses increased significantly to $27.6 million for Q3 2025, compared to $6.5 million in Q3 2024, primarily due to increased personnel and marketing expenses [7] - Research and Development (R&D) expenses decreased to $3.8 million for Q3 2025, down from $6.5 million in Q3 2024, reflecting the completion of clinical trials [8] Net Loss - The net loss for the three months ended September 30, 2025, was $16.7 million, compared to a net loss of $10.2 million during the same period in 2024 [9][22] - For the nine months ended September 30, 2025, the net loss was $46.2 million, compared to $37.1 million in the same period in 2024 [9][22]

Core Viewpoint - LENZ Therapeutics has launched VIZZ, the first FDA-approved aceclidine-based eye drop for treating presbyopia, which affects approximately 128 million adults in the U.S. The product is expected to be commercially available by mid-Q4 2025 [1][7]. Product Overview - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to improve near vision for up to 10 hours and is administered as a once-daily eye drop [3][4]. - The mechanism of action involves a predominantly pupil-selective miotic effect, contracting the iris sphincter muscle to create a pinhole effect that enhances depth of focus without causing a myopic shift [1][4]. Clinical Efficacy - In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes of application, with effects lasting up to 10 hours [1][4]. Market Potential - Presbyopia is a common age-related condition impacting nearly all individuals over 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [2][5]. - The global market for presbyopia treatments is significant, with an estimated 1.8 billion people affected worldwide [7]. Company Strategy - LENZ Therapeutics is focused on commercializing VIZZ in the U.S. and establishing international licensing partnerships to expand global access [7].

Core Viewpoint - LENZ Therapeutics is focused on the commercialization of VIZZ™, the first FDA-approved aceclidine-based eye drop for treating presbyopia, and will participate in several upcoming investor and medical conferences to present VIZZ [1][11]. Company Information - LENZ Therapeutics is headquartered in San Diego, California, and is dedicated to providing access to VIZZ globally through licensing partnerships [11]. - The company is targeting a significant market, with presbyopia affecting approximately 1.8 billion people worldwide and 128 million in the United States [11]. Product Details - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [7]. - The product works by causing contraction of the iris sphincter muscle, creating a pinhole effect that enhances depth of focus [7]. Upcoming Conferences - LENZ Therapeutics will participate in several conferences, including: - Citi's 2025 BioPharma Back to School Conference on September 2-3, 2025, in Boston, MA [2]. - Cantor Global Healthcare Conference on September 4, 2025, in New York City, NY [2]. - H.C. Wainwright 27 Annual Global Investment Conference on September 9, 2025, in New York City, NY [2]. - Morgan Stanley 23 Annual Global Healthcare Conference on September 10, 2025, in New York City, NY [3]. - Academy 2025 on October 8-9, 2025, in Boston, MA, featuring presentations on the efficacy of VIZZ [4].

Core Viewpoint - LENZ Therapeutics has received FDA approval for VIZZ, the first aceclidine-based eye drop for treating presbyopia, which affects approximately 128 million adults in the U.S. This product is expected to be available in the U.S. by October 2025, with a once-daily dosing regimen that provides near vision improvement for up to 10 hours [1][2][12]. Group 1: Product Information - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [8][9]. - The mechanism of action involves contracting the iris sphincter muscle to create a pinhole effect, enhancing depth of focus without causing a myopic shift [2][8]. - The FDA approval was based on three Phase 3 studies, demonstrating significant near vision improvement within 30 minutes and lasting up to 10 hours [3][4]. Group 2: Clinical Trials and Efficacy - In the CLARITY 1 and CLARITY 2 studies, VIZZ met all primary and secondary endpoints for near vision improvement, with consistent results across both trials [4]. - The trials involved 466 participants in CLARITY 1 and CLARITY 2, and 217 participants in CLARITY 3, which assessed long-term safety over six months [3][4]. - VIZZ was well-tolerated, with no serious treatment-related adverse events reported during over 30,000 treatment days [4][11]. Group 3: Market Impact and Future Plans - The approval of VIZZ is seen as a transformative advancement in treatment options for presbyopia, potentially becoming the standard of care for optometrists and ophthalmologists [2][3]. - The company plans to initiate direct-to-eye care professional sales and marketing activities immediately following the approval [1][2]. - LENZ Therapeutics aims to establish international licensing partnerships to expand access to VIZZ globally [12].